{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:33:19Z","timestamp":1792510399670,"version":"4.5.0"},"reference-count":79,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005620","name":"North Carolina GlaxoSmithKline Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005620","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.jaip.2019.11.020","type":"journal-article","created":{"date-parts":[[2020,2,6]],"date-time":"2020-02-06T04:10:16Z","timestamp":1580962216000},"page":"442-450","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"title":["Diagnosis and Management of T2-High Asthma"],"prefix":"10.1016","volume":"8","author":[{"given":"Andrea M.","family":"Coverstone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max A.","family":"Seibold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2019.11.020_bib1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/ni.3049","article-title":"The immunology of asthma","volume":"16","author":"Lambrecht","year":"2015","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jaip.2019.11.020_bib2","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0031-6997(24)01381-4","article-title":"Inflammatory mediators of asthma: an update","volume":"50","author":"Barnes","year":"1998","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.jaip.2019.11.020_bib3","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1164\/ajrccm.154.5.8912771","article-title":"IL-4 and IL-5 mRNA and protein in bronchial biopsies from patients with atopic and nonatopic asthma: evidence against \u201cintrinsic\u201d asthma being a distinct immunopathologic entity","volume":"154","author":"Humbert","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2019.11.020_bib4","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1056\/NEJM199201303260504","article-title":"Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma","volume":"326","author":"Robinson","year":"1992","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2019.11.020_bib5","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1126\/science.282.5397.2261","article-title":"Requirement for IL-13 independently of IL-4 in experimental asthma","volume":"282","author":"Grunig","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.jaip.2019.11.020_bib6","doi-asserted-by":"crossref","first-page":"15858","DOI":"10.1073\/pnas.0707413104","article-title":"Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids","volume":"104","author":"Woodruff","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaip.2019.11.020_bib7","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1056\/NEJM199010113231505","article-title":"Eosinophilic inflammation in asthma","volume":"323","author":"Bousquet","year":"1990","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2019.11.020_bib8","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1164\/ajrccm.160.3.9812110","article-title":"Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics","volume":"160","author":"Wenzel","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2019.11.020_bib9","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.jaci.2010.03.003","article-title":"Accumulation of intraepithelial mast cells with a unique protease phenotype in T(H)2-high asthma","volume":"125","author":"Dougherty","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.11.020_bib10","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1164\/rccm.201002-0295OC","article-title":"Mast cell phenotype, location, and activation in severe asthma: data from the Severe Asthma Research Program","volume":"183","author":"Balzar","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2019.11.020_bib11","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1164\/rccm.201807-1291OC","article-title":"A\u00a0transcriptomic method to determine airway immune dysfunction in T2-high and T2-low asthma","volume":"199","author":"Peters","year":"2019","journal-title":"Am J Respir Crit Care"},{"key":"10.1016\/j.jaip.2019.11.020_bib12","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jaci.2013.07.036","article-title":"Measures of gene expression in sputum cells can identify TH2-high and TH2-low subtypes of asthma","volume":"133","author":"Peters","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.11.020_bib13","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2019.11.020_bib14","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2019.11.020_bib15","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2019.11.020_bib16","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","article-title":"Dupilumab in persistent asthma with elevated eosinophil levels","volume":"368","author":"Wenzel","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2019.11.020_bib17","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1183\/09031936.93.06091368","article-title":"Increased amount of nitric oxide in exhaled air of asthmatics","volume":"6","author":"Alving","year":"1993","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2019.11.020_bib18","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1183\/09031936.96.09122671","article-title":"Nitric oxide in exhaled air","volume":"9","author":"Lundberg","year":"1996","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2019.11.020_bib19","first-page":"FC01","article-title":"Clinical utility of fractional exhaled nitric oxide (FeNO) as a biomarker to predict severity of disease and response to inhaled corticosteroid (ICS) in asthma patients","volume":"10","author":"Neelamegan","year":"2016","journal-title":"J\u00a0Clin Diagn Res"},{"key":"10.1016\/j.jaip.2019.11.020_bib20","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1183\/09031936.00012415","article-title":"Biomarkers to identify sputum eosinophilia in different adult asthma phenotypes","volume":"46","author":"Westerhof","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2019.11.020_bib21","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1136\/thoraxjnl-2014-205634","article-title":"External validation of blood eosinophils, FE(NO) and serum periostin as surrogates for sputum eosinophils in asthma","volume":"70","author":"Wagener","year":"2015","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2019.11.020_bib22","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/2045-7022-3-24","article-title":"A\u00a0qPCR-based metric of Th2 airway inflammation in asthma","volume":"3","author":"Bhakta","year":"2013","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.jaip.2019.11.020_bib23","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaci.2017.12.1009","article-title":"Refractory airway type 2 inflammation in a large subgroup of asthmatic patients treated with inhaled corticosteroids","volume":"143","author":"Peters","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.11.020_bib24","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2019.11.020_bib25","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.jaci.2012.06.025","article-title":"Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients","volume":"130","author":"Jia","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.11.020_bib26","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/pai.12575","article-title":"Periostin as a biomarker for the diagnosis of pediatric asthma","volume":"27","author":"Inoue","year":"2016","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaip.2019.11.020_bib27","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.rmed.2019.04.010","article-title":"Periostin, type 2 biomarker, is not associated with asthma control grade in asthmatic allergic children","volume":"151","author":"Licari","year":"2019","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2019.11.020_bib28","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.rmed.2018.08.005","article-title":"Disconnect of type 2 biomarkers in severe asthma; dominated by FeNO as a predictor of exacerbations and periostin as predictor of reduced lung function","volume":"143","author":"Mansur","year":"2018","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2019.11.020_bib29","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/pai.12457","article-title":"Predicting asthma morbidity in children using proposed markers of Th2-type inflammation","volume":"26","author":"Konradsen","year":"2015","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaip.2019.11.020_bib30","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jaip.2018.03.004","article-title":"Type 2 biomarkers and prediction of future exacerbations and lung function decline in adult asthma","volume":"6","author":"Semprini","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2019.11.020_bib31","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1164\/rccm.200903-0392OC","article-title":"T-helper type 2-driven inflammation defines major subphenotypes of asthma","volume":"180","author":"Woodruff","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2019.11.020_bib32","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1172\/JCI95693","article-title":"Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction","volume":"128","author":"Dunican","year":"2018","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jaip.2019.11.020_bib33","doi-asserted-by":"crossref","first-page":"eaaw4295","DOI":"10.1126\/science.aaw4295","article-title":"Protein crystallization promotes type 2 immunity and is reversible by antibody treatment","volume":"364","author":"Persson","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.jaip.2019.11.020_bib34","doi-asserted-by":"crossref","first-page":"6233","DOI":"10.4049\/jimmunol.162.10.6233","article-title":"IL-4 induces mucin gene expression and goblet cell metaplasia in\u00a0vitro and in\u00a0vivo","volume":"162","author":"Dabbagh","year":"1999","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaip.2019.11.020_bib35","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jaci.2013.11.025","article-title":"Dissecting childhood asthma with nasal transcriptomics distinguishes subphenotypes of disease","volume":"133","author":"Poole","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.11.020_bib36","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1056\/NEJMoa1814917","article-title":"Mometasone or tiotropium in mild asthma with a low sputum eosinophil level","volume":"380","author":"Lazarus","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2019.11.020_bib37","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaci.2006.11.639","article-title":"Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute\u2019s Severe Asthma Research Program","volume":"119","author":"Moore","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.11.020_bib38","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12931-015-0299-y","article-title":"Asthma characteristics and biomarkers from the Airways Disease Endotyping for Personalized Therapeutics (ADEPT) longitudinal profiling study","volume":"16","author":"Silkoff","year":"2015","journal-title":"Respir Res"},{"key":"10.1016\/j.jaip.2019.11.020_bib39","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12931-017-0524-y","article-title":"Cluster analysis of sputum cytokine-high profiles reveals diversity in T(h)2-high asthma patients","volume":"18","author":"Seys","year":"2017","journal-title":"Respir Res"},{"key":"10.1016\/j.jaip.2019.11.020_bib40","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02135-2016","article-title":"T-helper cell type 2 (Th2) and non-Th2 molecular phenotypes of asthma using sputum transcriptomics in U-BIOPRED","volume":"49","author":"Kuo","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2019.11.020_bib41","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/cea.13137","article-title":"Simultaneously elevated FeNO and blood eosinophils relate to asthma morbidity in asthmatics from NHANES 2007-12","volume":"48","author":"Mogensen","year":"2018","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2019.11.020_bib42","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1164\/rccm.201602-0419OC","article-title":"Inflammatory and comorbid features of patients with severe asthma and frequent exacerbations","volume":"195","author":"Denlinger","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2019.11.020_bib43","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1164\/rccm.201607-1453OC","article-title":"Effects of age and disease severity on systemic corticosteroid responses in asthma","volume":"195","author":"Phipatanakul","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2019.11.020_bib44","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1089\/ped.2010.0021","article-title":"Severe asthma in children: insights from the National Heart, Lung, and Blood Institute\u2019s Severe Asthma Research Program","volume":"23","author":"Fitzpatrick","year":"2010","journal-title":"Pediatr Allergy Immunol Pulmonol"},{"key":"10.1016\/j.jaip.2019.11.020_bib45","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.jaci.2010.11.015","article-title":"Heterogeneity of severe asthma in childhood: confirmation by cluster analysis of children in the National Institutes of Health\/National Heart, Lung, and Blood Institute Severe Asthma Research Program","volume":"127","author":"Fitzpatrick","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.11.020_bib46","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jaip.2017.05.032","article-title":"Baseline features of the Severe Asthma Research Program (SARP III) cohort: differences with age","volume":"6","author":"Teague","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2019.11.020_bib47","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/MCP.0000000000000342","article-title":"T2-low asthma: current approach to diagnosis and therapy","volume":"23","author":"Samitas","year":"2017","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.jaip.2019.11.020_bib48","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.jaci.2012.01.059","article-title":"Pediatric severe asthma is characterized by eosinophilia and remodeling without T(H)2 cytokines","volume":"129","author":"Bossley","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.11.020_bib49","series-title":"Global strategy for asthma management and prevention","year":"2019"},{"key":"10.1016\/j.jaip.2019.11.020_bib50","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1067\/mai.2001.117880","article-title":"Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma","volume":"108","author":"Busse","year":"2001","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.11.020_bib51","doi-asserted-by":"crossref","first-page":"e0183869","DOI":"10.1371\/journal.pone.0183869","article-title":"The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: the ASTERIX Observational study","volume":"12","author":"Bhutani","year":"2017","journal-title":"Plos One"},{"key":"10.1016\/j.jaip.2019.11.020_bib52","doi-asserted-by":"crossref","first-page":"250","DOI":"10.2500\/aap.2017.38.4067","article-title":"Efficacy and safety of omalizumab in children and adolescents with moderate-to-severe asthma: a systematic literature review","volume":"38","author":"Corren","year":"2017","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaip.2019.11.020_bib53","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1710-1492-9-47","article-title":"Reduction in oral corticosteroid use in patients receiving omalizumab for allergic asthma in the real-world setting","volume":"9","author":"Braunstahl","year":"2013","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaip.2019.11.020_bib54","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1378\/chest.10-1194","article-title":"Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review","volume":"139","author":"Rodrigo","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2019.11.020_bib55","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jaip.2018.04.043","article-title":"Omalizumab effectiveness by biomarker status in patients with asthma: evidence from PROSPERO, a prospective real-world study","volume":"7","author":"Casale","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2019.11.020_bib56","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2019.11.020_bib57","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJMoa0808991","article-title":"Mepolizumab and exacerbations of refractory eosinophilic asthma","volume":"360","author":"Haldar","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2019.11.020_bib58","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2019.11.020_bib59","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2019.11.020_bib60","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S2213-2600(16)30031-5","article-title":"Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies","volume":"4","author":"Ortega","year":"2016","journal-title":"Lancet Resp Med"},{"key":"10.1016\/j.jaip.2019.11.020_bib61","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1164\/rccm.201103-0396OC","article-title":"Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study","volume":"184","author":"Castro","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2019.11.020_bib62","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.chest.2016.03.032","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study","volume":"150","author":"Bjermer","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2019.11.020_bib63","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.chest.2016.03.018","article-title":"Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts","volume":"150","author":"Corren","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2019.11.020_bib64","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jaip.2018.08.021","article-title":"Effects of reslizumab on asthma outcomes in a subgroup of eosinophilic asthma patients with self-reported chronic rhinosinusitis with nasal polyps","volume":"7","author":"Weinstein","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2019.11.020_bib65","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.jaip.2017.08.024","article-title":"Long-term safety and efficacy of reslizumab in patients with eosinophilic asthma","volume":"5","author":"Murphy","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2019.11.020_bib66","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2019.11.020_bib67","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-2600(17)30344-2","article-title":"Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies","volume":"6","author":"FitzGerald","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2019.11.020_bib68","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2019.11.020_bib69","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S2213-2600(17)30190-X","article-title":"Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"5","author":"Ferguson","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2019.11.020_bib70","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","article-title":"Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta(2) agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial","volume":"388","author":"Wenzel","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2019.11.020_bib71","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jaip.2019.11.020_bib72","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jaci.2017.11.051","article-title":"Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma","volume":"142","author":"Weinstein","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.11.020_bib73","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S2213-2600(18)30406-5","article-title":"Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial","volume":"7","author":"Busse","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2019.11.020_bib74","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.jaci.2019.08.005","article-title":"Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype","volume":"144","author":"Gupta","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.11.020_bib75","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1002\/ppul.24508","article-title":"Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma","volume":"54","author":"Gupta","year":"2019","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jaip.2019.11.020_bib76","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jaci.2018.08.031","article-title":"Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: indirect treatment comparison","volume":"143","author":"Busse","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.11.020_bib77","doi-asserted-by":"crossref","first-page":"1801393","DOI":"10.1183\/13993003.01393-2018","article-title":"Matching-adjusted indirect comparison of benralizumab versus interleukin-5 inhibitors for the treatment of severe asthma: a systematic review","volume":"52","author":"Bourdin","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2019.11.020_bib78","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.jaci.2013.11.026","article-title":"Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis","volume":"133","author":"Haldar","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.11.020_bib79","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.jaci.2018.09.033","article-title":"Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma","volume":"143","author":"Khatri","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219819309602?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219819309602?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:22:20Z","timestamp":1761974540000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219819309602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":79,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S2213219819309602"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2019.11.020","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnosis and Management of T2-High Asthma","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2019.11.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}